The diagnostic value of CEA for lung cancer-related malignant pleural effusion in China: a meta-analysis

Expert Rev Respir Med. 2022 Jan;16(1):99-108. doi: 10.1080/17476348.2021.1941885. Epub 2021 Jun 24.

Abstract

Objective: To accurately evaluate the diagnostic value of carcinoembryonic antigen (CEA) for malignant pleural effusion associated with lung cancer in the Chinese population.

Methods: Three English databases, PubMed, Embase and Web of Science, and two Chinese databases, China National Knowledge Infrastructure (CNKI) and Wanfang Data, up to 5 November 2020, were searched. The literature on the diagnosis of lung cancer-related malignant pleural effusion by CEA in the Chinese population were collected. The data was analyzed by Stata15.0 software.

Results: A total of 15 studies were included in the meta-analysis. The combined sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio were 0.80 (95% CI: 0.74-0.84), 0.92 (95% CI: 0.89-0.95), 10.46 (95% CI: 7.29-15.00), 0.22 (95% CI: 0.17-0.28), 47.26 (95% CI: 28.84-77.44), respectively . The area under the receiver operating characteristic curve was 0.93 (95% CI: 0.91-0.95). No significant publication bias was found (P > 0.05).

Conclusion: CEA has anexcellent diagnostic value for patients with lung cancer-related malignant pleural effusion in the Chinese population.

Keywords: Carcinoembryonic antigen; diagnosis; lung cancer; malignant pleural effusion; meta-analysis.

Publication types

  • Meta-Analysis

MeSH terms

  • Biomarkers, Tumor
  • Carcinoembryonic Antigen
  • Humans
  • Lung Neoplasms* / complications
  • Lung Neoplasms* / diagnosis
  • Pleural Effusion*
  • Pleural Effusion, Malignant* / diagnosis
  • Pleural Effusion, Malignant* / etiology
  • ROC Curve
  • Sensitivity and Specificity

Substances

  • Biomarkers, Tumor
  • Carcinoembryonic Antigen